Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar ...
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the ...
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
A genetic medicine from Ionis Pharmaceuticals designed to reduce high levels of cholesterol has achieved the main goal of a Phase 2 study, but the results are short of what partner AstraZeneca hoped ...
The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.’s IONS Tryngolza (olezarsen) to ...
Zacks Investment Research on MSN
IONS out-licenses ex-US rights for rare neurology drug to Recordati
Ionis Pharmaceuticals IONS signed a license agreement with Italy-based Recordati. Per the terms, Recordati will acquire ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo (Reuters) - Biogen and Ionis Pharmaceuticals said on ...
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...
Jan 22 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab said on Monday its experimental drug reduced the occurrence of painful attacks in patients with a rare genetic disease that triggers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results